A Novel Polyacrylamide Magnetic Nanoparticle Contrast Agent for Molecular Imaging using MRI

Molecular Imaging

Volumn 2, Issue 4, 2003, Pages 324-332

  Moffat, Bradford A ^a   Ramachandra Ready, G ^b   McConville, Patrick ^b   Hall, Daniel E ^a   Chenevert, Thomas L ^a   Kopelman, Raoul R ^a   Philbert, Martin ^a   Weissleder, Ralph ^c   Rehemtulla, Alnawaz ^a   Ross, Brian D ^a,d  

^a UNIVERSITY OF MICHIGAN   (United States)

^b Molecular Therapeutics Inc   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d Center for Molecular Imaging   (United States)

Author keywords

Cancer; Molecular imaging; MRI contrast agent; Nanoparticles; Polyacrylamide (PA); Polyacrylamide magnetic (PAM) nanoparticle; Polyethylene glycol (PEG); Superparamagnetic iron oxide (SPIO)

Indexed keywords

MOLECULAR IMAGING; MRI CONTRAST AGENTS; POLYACRYLAMIDE MAGNETIC (PAM) NANOPARTICLES;

BLOOD; IRON OXIDES; NANOSTRUCTURED MATERIALS; POLYAMIDES; POLYCRYSTALLINE MATERIALS; POLYETHYLENE GLYCOLS; SUPERPARAMAGNETISM; TUMORS;

MAGNETIC RESONANCE IMAGING;

ACRYLIC ACID RESIN; CONTRAST MEDIUM; MACROGOL DERIVATIVE; POLYACRYLAMIDE;

ANIMAL; ARTICLE; BRAIN TUMOR; CELL CULTURE; CHEMISTRY; FISCHER 344 RAT; HALF LIFE TIME; MALE; METHODOLOGY; NANOTECHNOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; RAT;

ACRYLIC RESINS; ANIMALS; BRAIN NEOPLASMS; CONTRAST MEDIA; HALF-LIFE; MAGNETIC RESONANCE IMAGING; MALE; NANOTECHNOLOGY; PARTICLE SIZE; POLYETHYLENE GLYCOLS; RATS; RATS, INBRED F344; TUMOR CELLS, CULTURED;

EID: 9144262307     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.1162/153535003322750664     Document Type: Article

References (28)

1. Brigger I, Dubernet C, Couvreur P (2002). Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 54:631-651.
2. Gambhir SS, Herschman HR, Cherry SR, Barrio JR, Satyamurthy N, Toyokuni T, Phelps ME, Larson SM, Balatoni J, Finn R, Sadelain M, Tjuvajev J, Blasberg R (2000). Imaging transgene expression with radionuclide imaging technologies. Neoplasia. 2:118-138.
3. Burt BM, Humm JL, Kooby DA, Squire OD, Mastorides S, Larson SM, Fong Y (2001). Using positron emission tomography with [(18)F]FDG to predict tumor behavior in experimental colorectal cancer. Neoplasia. 3:189-195.
4. Ponomarev V, Doubrovin M, Lyddane C, Beresten T, Balatoni J, Bornman W, Finn R, Akhurst T, Larson S, Blasberg R, Sadelain M, Tjuvajev J (2001). Imaging TCR-dependent NFAT-mediated T-cell activation with positron emission tomography in vivo. Neoplasia. 3:480-488.
5. Contag CH, Ross BD (2002). It's not just about anatomy: In vivo bioluminescence imaging as an eyepiece into biology. J Magn Reson Imaging. 16:378-387.
6. Bogdanov AA Jr, Lin CP, Simonova M, Matuszewski L, Weissleder R (2002). Cellular activation of the self-quenched fluorescent reporter probe in tumor microenvironment. Neoplasia. 4:228-236.
7. Ntziachristos V, Yodh AG, Schnall MD, Chance B (2002). MRI-guided diffuse optical spectroscopy of malignant and benign breast lesions. Neoplasia. 4:347-354.
8. Rehemtulla A, Hall DE, Stegman LD, Prasad U, Chen G, Bhojani MS, Chenevert TL, Ross BD (2002). Molecular imaging of gene expression and efficacy following adenoviral-mediated brain tumor gene therapy. Mol Imaging. 1:43-55.
9. Fleige G, Noltle C, Synowitz M, Seeberger F, Kettenmann H, Zimmer C (2001). Magnetic labeling of activated microglia in experimental gliomas. Neoplasia. 3:489-499.
10. Messerli SM, Tang Y, Giovannini M, Bronson R, Weissleder R, Breakefield XO (2002). Detection of spontaneous schwannomas by MRI in a transgenic murine model of neurofibromatosis type 2. Neoplasia. 4:501-509.
11. Koutcher JA, Hu X, Xu S, Gade T, Leeds N, Zhou XJ, Zagzag D, Holland EC (2002). MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. Neoplasia. 4:480-485.
12. Jennings D, Hatton BN, Guo J, Galons J-P, Trouard T, Raghunand N, Marshall J, Gillies R (2002). Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI. Neoplasia. 4:255-262.
13. Weissleder R, Moore A, Mahmood U, Bhorade R, Benveniste H, Chiocca EA, Basilion JP (2000). In vivo magnetic resonance imaging of transgene expression. Nat Med. 6:351-355.
14. Lewin M, Carlesso N, Tung C, Tang X, Cory D, Scadden D, Weissleder R (2000). Tat peptide-derivatized magnetic nano-particles allow in vive tracking and recovery of progenitor cells. Nat Biotechnol. 18:410-414.
15. Rainov NG, Zimmer C, Chase M, Cramm CM, Chiocca EA, Weissleder R, Breakefield XO (1995). Selective uptake of viral and monocrystalline particles delivered intra-arterially to experimental brain neoplasms. Hum Gene Ther. 6:1543-1552.
16. Zimmer C, Weissleder R, Poss K, Bogdanov A, Wright SC, Jr., Enochs WS (1995). AIR imaging of phagocytosis in experimental gliomas. Radiology. 197:533-538.
17. Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L (2002). Annexin V-CLIO: A nanoparticle for detecting apoptosis by MRI. Mol Imaging. 1:102-107.
18. Wunderbaldinger P, Josephson L, Weissleder R (2002). Cross-linked iron oxides (CLIO): A new platform for the development of targeted MR contrast agents. Acad Radiol. 9:S304-S306.
19. Bremer C, Mustafa M, Bogdanov A Jr, Ntziachristos V, Petrovsky A, Weissleder R (2003). Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. Radiology. 226:214-220.
20. Koenig SH, Kellar KE (1995). Theory of 1/T1 and 1/T2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med. 34:227-233.
21. Wang YX, Hussain SM, Krestin GP (2001). Superparamagnetic iron oxide contrast agents: Physicochemical characteristics and applications in MR imaging. Eur Radiol. 11:2319-2331.
22. Le Duc G, Peoc'h M, Remy C, Charpy O, Muller RN, Lebas J-F, Decorps M (1999). Use of T(2)-weighted susceptibility contrast MRI for mapping the blood volume in the glioma-bearing rat brain. Magn Reson Med. 42:754-761.
23. Kim JA (2003). Targeted therapies for the treatment of cancer. Am J Surg. 186:264-268.
24. Weissleder R, Mahmood U (2001). Molecular imaging. Radiology. 219:316-333.
25. Gelovani Tjuvajev J, Blasberg RG (2003). In vivo imaging of molecular-genetic targets for cancer therapy. Cancer Cell. 3:327-332.
26. Hogemann D, Ntziachristos V, Josephson L, Weissleder R (2002). High throughput magnetic resonance imaging for evaluating targeted nanoparticle probes. Bioconjug Chem. 13: 116-121.
27. Moore A, Weissleder R, Bogdanov A Jr (1997). Uptake of dextrancoated monocrystalline iron oxides in tumor cells and macrophages. J Magn Reson Imaging. 7:1140-1145.
28. Tropres I, Grimault S, Väth A, Grillon E, Julien C, Payen JF, Lamalle L, Decorps M (2001). Vessel size imaging. Magn Reson Med. 45:397-408.